AORT · Artivion, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-12 | Holloway Jean F |
SVP, General Counsel |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects the price the shares were sold. |
Common Stock
|
977 |
| 2026-06-11 | GREEN ANDREW M |
VP Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. Reflects weighted average price. Range of prices were between $20.24 to $21.02. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
30,000 |
| 2026-06-11 | GREEN ANDREW M |
VP Regulatory |
Convert↓
Filing footnotes — Stock Options (Right to buy) (Direct)
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. Stock options vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. |
Stock Options (Right to buy)
|
30,000 |
| 2026-06-11 | GREEN ANDREW M |
VP Regulatory |
Convert↓
Filing footnotes — Stock Options (Right to buy) (Direct)
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. Stock options vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. |
Stock Options (Right to buy)
|
14,001 |
| 2026-06-11 | GREEN ANDREW M |
VP Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. Reflects weighted average price. Range of prices were between $20.25 to $21.02. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
14,001 |
| 2026-06-11 | GREEN ANDREW M |
VP Regulatory |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. |
Common Stock
|
14,001 |
| 2026-06-11 | GREEN ANDREW M |
VP Regulatory |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. |
Common Stock
|
30,000 |
| 2026-06-02 | SEMEDO ANTHONY B. |
Director |
Other↓
Filing footnotes — Common Stock (Direct)
Represents a transfer of shares from the Reporting Person's directly held account to an account held by the Stacie Nelson and Anthony Semedo Living Trust. The transfer was made for estate planning purposes, involved no sale or other disposition for value, and resulted only in a change in the form of beneficial ownership from direct to indirect. |
Common Stock
|
6,325 |
| 2026-06-02 | SEMEDO ANTHONY B. |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents a transfer of shares from the Reporting Person's directly held account to an account held by the Stacie Nelson and Anthony Semedo Living Trust. The transfer was made for estate planning purposes, involved no sale or other disposition for value, and resulted only in a change in the form of beneficial ownership from direct to indirect. The shares of common stock are held of record by the Stacie Nelson and Anthony Semedo Living Trust, a revocable living trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust and may be deemed to beneficially own such shares. |
Common Stock
(I)
|
6,325 |
| 2026-05-18 | Burbank Jeffrey H |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-05-18 | Salveson Jon W |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-05-18 | SEMEDO ANTHONY B. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. Mr. Semedo also indirectly owns 600 shares through his spouse. |
Common Stock
|
7,576 |
| 2026-05-18 | Borgstrom Marna P |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This amendment is being filed solely to correct an administrative error in the transaction date, number of shares granted and owned, and vesting date reported in the original Form 4. The restricted stock award was granted on May 18, 2026, rather than May 14, 2026 as previously reported; consisted of 7,576 shares, rather than 7,850 shares as previously reported; will vest on May 18, 2027, rather than May 14, 2027 as previously reported; and the amount of securities beneficially owned is 56,664, rather than 56,938 as previously reported. No other changes are being made by this amendment. RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-05-18 | BEVEVINO DANIEL J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-05-18 | ACKERMAN THOMAS F |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-05-18 | Hoff Elizabeth A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-05-18 | Bullock James |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
7,576 |
| 2026-03-04 | Holloway Jean F |
SVP, General Counsel |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects the price the shares were sold. |
Common Stock
|
8,962 |
| 2026-03-03 | Davis John E |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
4,573 |
| 2026-03-03 | Stanton Marshall S. |
SVP, Clinical & MD Affair |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
2,149 |
| 2026-03-03 | Holloway Jean F |
SVP, General Counsel |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
3,843 |
| 2026-03-03 | Berry Lance A |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
6,316 |
| 2026-03-03 | Horton Amy |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
901 |
| 2026-03-03 | Mackin James P |
President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
17,887 |
| 2026-03-02 | Horton Amy |
VP, Chief Accounting Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
Common Stock
|
7,475 |
| 2026-03-02 | Mackin James P |
President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
14,911 |
| 2026-03-02 | Holloway Jean F |
SVP, General Counsel |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
2,183 |
| 2026-03-02 | Holloway Jean F |
SVP, General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
Common Stock
|
27,795 |
| 2026-03-02 | Mackin James P |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
Common Stock
|
116,948 |
| 2026-03-02 | Berry Lance A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
Common Stock
|
40,874 |
| 2026-03-02 | Davis John E |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
Common Stock
|
28,845 |
| 2026-03-02 | Horton Amy |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
641 |
| 2026-03-02 | Stanton Marshall S. |
SVP, Clinical & MD Affair |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. |
Common Stock
|
21,838 |
| 2026-03-02 | Stanton Marshall S. |
SVP, Clinical & MD Affair |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
1,513 |
| 2026-03-02 | Davis John E |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
2,784 |
| 2026-03-02 | Berry Lance A |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
5,178 |
| 2026-02-24 | Holloway Jean F |
SVP, General Counsel |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
1,668 |
| 2026-02-24 | Horton Amy |
VP, Chief Accounting Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
5,658 |
| 2026-02-24 | Davis John E |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
2,075 |
| 2026-02-24 | Stanton Marshall S. |
SVP, Clinical & MD Affair |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
1,259 |
| 2026-02-24 | Davis John E |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
20,438 |
| 2026-02-24 | Berry Lance A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
37,482 |
| 2026-02-24 | Mackin James P |
President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
13,936 |
| 2026-02-24 | Horton Amy |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
830 |
| 2026-02-24 | Berry Lance A |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
4,485 |
| 2026-02-24 | Mackin James P |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
97,030 |
| 2026-02-24 | Holloway Jean F |
SVP, General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. |
Common Stock
|
20,085 |
| 2026-02-23 | Berry Lance A |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
4,981 |
| 2026-02-23 | Holloway Jean F |
SVP, General Counsel |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
3,079 |
| 2026-02-23 | Mackin James P |
President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Common Stock
|
20,962 |